One such example, is the bispecific antibody combination targeting OX40 and CTLA-4, which significantly enhanced CD8+ T cells and reduced Tregs specifically within the TME, leading to better tumor control than either therapy alone (178). This evidence concerns the gene CD8A and neoplasm.